We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Starting with Rosuvastatin in Primary Hyperlipidemia -- Is There More Than Lipid Lowering?
- Authors
Milionis, Haralampos J.; Gazi, Irene F.; Filippatos, Theodosios D.; Tzovaras, Vasilios; Chasiotis, George; Goudevenos, John; Seferiadis, Konstantine; Elisaf, Moses S.
- Abstract
The authors investigated the effects of rosuvastatin, beyond its lipid-lowering activity, on several nonlipid metabolic variables, along with its safety and tolerability, in patients treated for primary hyperlipidemia. Patients (n = 55) with primary hyperlipidemia were open-label assigned to the recommended starting dose of rosuvastatin 10 mg/day, and serum metabolic variables were measured at baseline and after 8 and 20 weeks. Treatment with rosuvastatin produced significant reductions in total cholesterol, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, nonhigh-density lipoprotein cholesterol (non HDL-C), and triglyceride concentrations, whereas HDL-C, apolipoprotein A-I, and lipoprotein(a) levels did not change significantly from baseline. The LDL-C treatment target was achieved in 71% of patients. No significant variations in renal function parameters (serum creatinine and creatinine clearance), insulin resistance estimates, and serum concentrations of uric acid, total homocysteine, vitamin B12, and folic acid were observed during the period of treatment. High-sensitivity C-reactive protein levels were significantly lowered by rosuvastatin therapy (median values, 3.1 vs 2.0 vs 1.9 mg/L, at 0, 8, and 20 weeks, respectively; p «0.0001). In conclusion, rosuvastatin at 10 mg/day is a highly effective, safe, and well-tolerated monotherapy option for patients with primary hyperlipidemia, with a favorable antiinflammatory potential and nondeteriorating effects on renal function.
- Subjects
ANTILIPEMIC agents; HYPERLIPIDEMIA; PHARMACODYNAMICS; LIPID metabolism disorders; LOW-cholesterol diet; DIABETES complications; DRUG resistance; DRUG efficacy
- Publication
Angiology, 2005, Vol 56, Issue 5, p585
- ISSN
0003-3197
- Publication type
Article
- DOI
10.1177/000331970505600510